Supplementary Figure S3 from Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA as a Prediagnostic Marker for Nasopharyngeal Carcinoma

Supplementary Figure S3 from Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA as a Prediagnostic Marker for Nasopharyngeal Carcinoma

<p>Detection of EBV-specific IgM in sera from incident NPC cases and healthy controls in the SCHS cohort. Heatmap depicting IgM heavy chain-specific (IgMH) normalized detection values from 20 incident NPC case-control pairs and the data is represented similarly to Fig 2 with Fisher’s exact tes...

Szczegółowa specyfikacja

Zapisane w:

Opis bibliograficzny
1. autor:	Sarita Paudel (15047430) (author)
Kolejni autorzy:	Benjamin E. Warner (15047433) (author), Renwei Wang (15047436) (author), Jennifer Adams-Haduch (15047439) (author), Alex S. Reznik (15047442) (author), Jason Dou (15047445) (author), Yufei Huang (10791191) (author), Yu-Tang Gao (15047448) (author), Woon-Puay Koh (15047451) (author), Alan Bäckerholm (15047454) (author), Jian-Min Yuan (15047457) (author), Kathy H.Y. Shair (15047460) (author)
Wydane:	2025
Hasła przedmiotowe:	Cancer Cancer Biology Cancer Detection and Diagnosis Therapeutic Research and Development Biomarkers Cancer risk biomarkers Serum biomarkers Head, Neck & Oral Cancers Translational Research Viral Oncogenesis Human tumor viruses
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy

Supplementary Figure S1 from Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA as a Prediagnostic Marker for Nasopharyngeal Carcinoma
od: Sarita Paudel (15047430)
Wydane: (2025)

Supplementary Figure S2 from Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA as a Prediagnostic Marker for Nasopharyngeal Carcinoma
od: Sarita Paudel (15047430)
Wydane: (2025)

Supplementary Figure S4 from Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA as a Prediagnostic Marker for Nasopharyngeal Carcinoma
od: Sarita Paudel (15047430)
Wydane: (2025)

Supplementary Figure S5 from Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA as a Prediagnostic Marker for Nasopharyngeal Carcinoma
od: Sarita Paudel (15047430)
Wydane: (2025)

Supplementary Figure S6 from Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA as a Prediagnostic Marker for Nasopharyngeal Carcinoma
od: Sarita Paudel (15047430)
Wydane: (2025)

Figure 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
od: Nicola S. Meagher (15048462)
Wydane: (2025)

Figure 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
od: Nicola S. Meagher (15048462)
Wydane: (2025)

Figure 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
od: Nicola S. Meagher (15048462)
Wydane: (2025)

Supplementary Tables S1-S11 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
od: Nicola S. Meagher (15048462)
Wydane: (2025)

Table 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
od: Nicola S. Meagher (15048462)
Wydane: (2025)

Table 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
od: Nicola S. Meagher (15048462)
Wydane: (2025)

Table 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
od: Nicola S. Meagher (15048462)
Wydane: (2025)

Supplementary Table S3 from Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma
od: Jun Wang (15051911)
Wydane: (2025)

Supplementary Table S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
od: Raphaël Leman (17314506)
Wydane: (2025)

Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
od: Raphaël Leman (17314506)
Wydane: (2025)

Supplementary Table S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
od: Raphaël Leman (17314506)
Wydane: (2025)

Supplementary Table S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
od: Raphaël Leman (17314506)
Wydane: (2025)

Supplementary Table S5 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
od: Raphaël Leman (17314506)
Wydane: (2025)

Supplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
od: Raphaël Leman (17314506)
Wydane: (2025)

Figure S1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Wydane: (2025)

Figure S2 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Wydane: (2025)

Figure S3 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Wydane: (2025)

Figure S4 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Wydane: (2025)

Figure S5 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Wydane: (2025)

Figure S6 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Wydane: (2025)

Supplementary Tables 1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Wydane: (2025)

Supplementary Table S4 from Blood-Based Diagnosis and Risk Stratification of Patients with Pancreatic Intraductal Papillary Mucinous Neoplasm (IPMN)
od: Chaoyang Zhang (15051876)
Wydane: (2025)

Supplementary Table S6 from Blood-Based Diagnosis and Risk Stratification of Patients with Pancreatic Intraductal Papillary Mucinous Neoplasm (IPMN)
od: Chaoyang Zhang (15051876)
Wydane: (2025)

Supplementary Table S1 from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma
od: Naveen S. Vasudev (15057037)
Wydane: (2025)

Supplementary Table S2 from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma
od: Naveen S. Vasudev (15057037)
Wydane: (2025)

Supplementary Figure S1 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
od: Rohit Thummalapalli (17314483)
Wydane: (2025)

Supplementary Figure S10 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
od: Rohit Thummalapalli (17314483)
Wydane: (2025)

Supplementary Figure S11 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
od: Rohit Thummalapalli (17314483)
Wydane: (2025)

Supplementary Figure S12 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
od: Rohit Thummalapalli (17314483)
Wydane: (2025)

Supplementary Figure S13 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
od: Rohit Thummalapalli (17314483)
Wydane: (2025)

Supplementary Figure S14 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
od: Rohit Thummalapalli (17314483)
Wydane: (2025)

Supplementary Figure S15 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
od: Rohit Thummalapalli (17314483)
Wydane: (2025)

Supplementary Figure S2 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
od: Rohit Thummalapalli (17314483)
Wydane: (2025)

Supplementary Figure S3 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
od: Rohit Thummalapalli (17314483)
Wydane: (2025)

Supplementary Figure S4 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
od: Rohit Thummalapalli (17314483)
Wydane: (2025)

Cannot write session to /tmp/vufind_sessions/sess_k2mjk8brgko78ccelop1r5gh6i